Skip to content

Study · Non-randomized trial · n = 5 · 1989

4 results

Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly.

van Liessum PA, Hopman WP, Pieters GF, Jansen JB, Smals AG, Rosenbusch G, Kloppenborg PW, Lamers CB

The Journal of clinical endocrinology and metabolism1 Sept 1989Cited by 58 (Europe PMC)

PMID2760170 (opens in a new tab)DOI10.1210/jcem-69-3-557 (opens in a new tab)PepBankPUB-02760170
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialMechanism

    In long-term octreotide-treated acromegaly, an octreotide injection completely suppressed postprandial gallbladder contraction versus placebo.

    In plain wordsIn acromegaly patients receiving long-term octreotide, an injection blocked gallbladder contraction after food versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePostprandial gallbladder contraction
    Study

    n = 5

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    SMS completely suppressed the postprandial gallbladder contraction, despite a blunted, though still statistically significant, increase in plasma CCK from 1.6 +/- 0.2 pmol/L to an average of 3.7 +/- 1.7 pmol/L (P less than 0.01).
    2 context sentences
    Summary · context
    The effects on gallbladder motility of long term treatment with the somatostatin analog SMS 201-995 (SMS) were studied in five patients with acromegaly treated for 6-32 months with 200-300 micrograms SMS daily.
    Summary · context
    SMS (100 micrograms) or placebo was injected sc 45 min before a standard breakfast.
  2. 02HumanNon-randomized trialMechanism

    In octreotide-treated acromegaly, the postprandial CCK rise was blunted versus placebo, although CCK increased from 1.6 +/- 0.2 to 3.7 +/- 1.7 pmol/L (P less than 0.01).

    In plain wordsIn acromegaly patients, octreotide blunted CCK release after food versus placebo, although CCK still increased.

    Peptide
    Octreotide
    Outcome
    DecreaseBlunted postprandial CCK release
    Study

    n = 5

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Plasma CCK before meal
    1.6 pmol/L
    after octreotide injection; +/- 0.2
    Plasma CCK average after meal
    3.7 pmol/L
    after octreotide injection; +/- 1.7

    Source sentences

    Summary
    SMS completely suppressed the postprandial gallbladder contraction, despite a blunted, though still statistically significant, increase in plasma CCK from 1.6 +/- 0.2 pmol/L to an average of 3.7 +/- 1.7 pmol/L (P less than 0.01).
    2 context sentences
    Summary · context
    The effects on gallbladder motility of long term treatment with the somatostatin analog SMS 201-995 (SMS) were studied in five patients with acromegaly treated for 6-32 months with 200-300 micrograms SMS daily.
    Summary · context
    SMS (100 micrograms) or placebo was injected sc 45 min before a standard breakfast.
  3. 03HumanNon-randomized trialMechanism

    In long-term octreotide-treated acromegaly, the postprandial pancreatic polypeptide peak with placebo became a slight decrease with octreotide (P less than 0.05).

    In plain wordsIn acromegaly, octreotide changed the pancreatic polypeptide rise after food with placebo to a slight fall.

    Peptide
    Octreotide
    Outcome
    DecreasePostprandial pancreatic polypeptide
    Study

    n = 5

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The postprandial plasma PP peak after placebo was replaced by a slight but statistically significant decrease after SMS (P less than 0.05).
    2 context sentences
    Summary · context
    The effects on gallbladder motility of long term treatment with the somatostatin analog SMS 201-995 (SMS) were studied in five patients with acromegaly treated for 6-32 months with 200-300 micrograms SMS daily.
    Summary · context
    SMS (100 micrograms) or placebo was injected sc 45 min before a standard breakfast.
  4. 04HumanObservational studyMechanism

    In long-term octreotide-treated acromegaly, CCK correlated significantly with gallbladder volume after placebo but not after octreotide.

    In plain wordsIn acromegaly, CCK and gallbladder volume were linked after placebo but had no significant link after octreotide.

    Peptide
    Octreotide
    Outcome
    Not applicableCCK and gallbladder volume correlation
    Study

    n = 5

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A statistically significant correlation between the plasma CCK values and corresponding gallbladder volumes was seen only after placebo injection, not in the SMS study.
    2 context sentences
    Summary · context
    The effects on gallbladder motility of long term treatment with the somatostatin analog SMS 201-995 (SMS) were studied in five patients with acromegaly treated for 6-32 months with 200-300 micrograms SMS daily.
    Summary · context
    SMS (100 micrograms) or placebo was injected sc 45 min before a standard breakfast.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.